Document Detail

Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy.
MedLine Citation:
PMID:  23151911     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To compare the performance of eight metabolic indices for the early assessment of tumour response in patients with metastatic colorectal cancer (mCRC) treated with chemotherapy.
METHODS: Forty patients with advanced mCRC underwent two FDG PET/CT scans, at baseline and on day 14 after chemotherapy initiation. For each lesion, eight metabolic indices were calculated: four standardized uptake values (SUV) without correction for the partial volume effect (PVE), two SUV with correction for PVE, a metabolic volume (MV) and a total lesion glycolysis (TLG). The relative change in each index between the two scans was calculated for each lesion. Lesions were also classified as responding and nonresponding lesions using the Response Evaluation Criteria In Solid Tumours (RECIST) 1.0 measured by contrast-enhanced CT at baseline and 6-8 weeks after starting therapy. Bland-Altman analyses were performed to compare the various indices. Based on the RECIST classification, ROC analyses were used to determine how accurately the indices predicted lesion response to therapy later seen with RECIST.
RESULTS: RECIST showed 27 responding and 74 nonresponding lesions. Bland-Altman analyses showed that the four SUV indices uncorrected for PVE could not be used interchangeably, nor could the two SUV corrected for PVE. The areas under the ROC curves (AUC) were not significantly different between the SUV indices not corrected for PVE. The mean SUV change in a lesion better predicted lesion response without than with PVE correction. The AUC was significantly higher for SUV uncorrected for PVE than for the MV, but change in MV provided some information regarding the lesion response to therapy (AUC >0.5).
CONCLUSION: In these mCRC patients, all SUV uncorrected for PVE accurately predicted the tumour response on day 14 after starting therapy as assessed 4 to 6 weeks later (i.e. 6 to 8 weeks after therapy initiation) using the RECIST criteria. Neither correcting SUV for PVE nor measuring TLG improved the assessment of tumour response compared to SUV uncorrected for PVE. The change in MV was the least accurate index for predicting tumour response.
Jacques-Antoine Maisonobe; Camilo A Garcia; Hatem Necib; Bruno Vanderlinden; Alain Hendlisz; Patrick Flamen; Irène Buvat
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2012-11-14
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  40     ISSN:  1619-7089     ISO Abbreviation:  Eur. J. Nucl. Med. Mol. Imaging     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-04     Completed Date:  2013-06-27     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  166-74     Citation Subset:  IM    
IMNC UMR 8165 CNRS - Paris 7 and Paris 11 Universities, Building 440, Orsay Campus, 91406 Orsay Cedex, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Colorectal Neoplasms / drug therapy*,  pathology*
Contrast Media / pharmacology
Drug Therapy, Combination / methods
Middle Aged
Models, Statistical
Neoplasm Metastasis
Positron-Emission Tomography / methods*
ROC Curve
Reproducibility of Results
Reg. No./Substance:
0/Contrast Media

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse ...
Next Document:  Clinical usefulness of breast-specific gamma imaging as an adjunct modality to mammography for diagn...